Trial Profile
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Semaglutide (Primary) ; Liraglutide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 19 Jul 2018 Primary endpoint has been met. (Change in HbA1c (Glycosylated haemoglobin))), as reported in an article published in the Diabetes Care
- 19 Jul 2018 Results published in the Diabetes Care
- 08 Nov 2016 Status changed from active, no longer recruiting to completed.